Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)

Trial Profile

Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 May 2015

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Lymphangioleiomyomatosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MIDAS
  • Most Recent Events

    • 06 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top